Výsledky vyhledávání - "James E. O'dorisio"

Supplemental Figure Legends from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Autor: Joseph A. Ludwig, James E. O'Dorisio, Kirk S. Culotta, Dannette K. Doolittle, Adrianna S. Buford, Rebecca L. Maywald, Ramani A. Aiyer, Vandhana Ramamoorthy, Brian A. Menegaz, Salah-Eddine Lamhamedi-Cherradi

Supplemental Figure Legends. Legends for all the four supplemental figures

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a39c1e0a4273114368735c1a938b803
https://doi.org/10.1158/1535-7163.22501944.v1

Zobrazit plný text záznamu

Supplemental Figure 1 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Supplemental Figure 1. Gene expression changes between sensitive and YK-resistant ES cell lines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7a91dbda7625f7135e74ca477cb93f
https://doi.org/10.1158/1535-7163.22501956.v1

Zobrazit plný text záznamu

Supplemental Figure 3 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Supplemental Figure 3. The YK-resistant clone (TC71#3)displayed cross resistance to imatinib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f996fb1afd803918859abd4161d6ae
https://doi.org/10.1158/1535-7163.22501950

Zobrazit plný text záznamu

Supplemental Materials and Methods from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Supplemental Materials and Methods. Gene expression profiling and analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c3af6416a8ec5ed3a3e339866cda755
https://doi.org/10.1158/1535-7163.22501941.v1

Zobrazit plný text záznamu

Supplemental Figure 4 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Supplemental Figure 4. Proteomic analysis of sensitive and resistant ES cell lines to YK-4-279

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ed6a98000ba165da4a2db376fd907d
https://doi.org/10.1158/1535-7163.22501947

Zobrazit plný text záznamu

Supplemental Figure 2 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Supplemental Figure 2. Nuclear, cytoplasmic and total RHA levels are identical between sensitive and YK-Resistant ES cell lines.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8bff659f99b7d0c4ee14a7794ff944
https://doi.org/10.1158/1535-7163.22501953

Zobrazit plný text záznamu

An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

Autor: Vandhana Ramamoorthy, Kirk S. Culotta, Ramani Aiyer, Rebecca L. Maywald, Joseph A. Ludwig, Adrianna S. Buford, Dannette K. Doolittle, Brian A. Menegaz, James E. O'dorisio, Salah Eddine Lamhamedi-Cherradi

Publikováno v: Molecular cancer therapeutics. 14(7)

Ewing sarcoma is a transcription factor–mediated pediatric bone tumor caused by a chromosomal translocation of the EWSR1 gene and one of several genes in the ETS family of transcription factors, typically FLI1 or ERG. Full activity of the resulting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a5bbf78db720327b6a4ab0497eef87
https://pubmed.ncbi.nlm.nih.gov/25964201

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání